Herold v. Salix Pharmaceuticals CA3

CourtCalifornia Court of Appeal
DecidedMay 7, 2013
DocketC071037
StatusUnpublished

This text of Herold v. Salix Pharmaceuticals CA3 (Herold v. Salix Pharmaceuticals CA3) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Herold v. Salix Pharmaceuticals CA3, (Cal. Ct. App. 2013).

Opinion

Filed 5/7/13 Herold v. Salix Pharmaceuticals CA3 NOT TO BE PUBLISHED California Rules of Court, rule 8.1115(a), prohibits courts and parties from citing or relying on opinions not certified for publication or ordered published, except as specified by rule 8.1115(b). This opinion has not been certified for publication or ordered published for purposes of rule 8.1115.

IN THE COURT OF APPEAL OF THE STATE OF CALIFORNIA THIRD APPELLATE DISTRICT (Placer) ----

ELDRIDGE HEROLD, C071037

Plaintiff and Appellant, (Super. Ct. No. SCV0028300)

v.

SALIX PHARMACEUTICALS, INC.,

Defendant and Respondent.

After using a bowel cleansing/purgative product manufactured by defendant Salix Pharmaceuticals, Inc., plaintiff Eldridge Herold had to be placed on dialysis treatment for kidney failure. In November 2007, one of his physicians told him that the product should not have been prescribed to him and that if he had not taken it he would not need dialysis. Herold did not commence this action against Salix until three years later. The trial court granted summary judgment to Salix on the ground that Herold‟s claims were time-barred

1 because Herold knew of his injury and of its cause more than two years before he commenced the action.1 As we will explain, the trial court properly granted Salix‟s motion for summary judgment. Under the delayed discovery rule, the plaintiff must not only know of his injury and its factual cause, but must also suspect the injury is due to someone‟s wrongdoing to begin the running of the statute of limitations. (Jolly v. Eli Lilly & Co. (1988) 44 Cal.3d 1103, 1110 (Jolly).) Here, the undisputed evidence shows that more than two years before he brought suit against Salix, Herold had sufficient information to cause a reasonable person to suspect his injuries were caused by wrongdoing. Accordingly, we shall affirm. FACTUAL AND PROCEDURAL BACKGROUND The basic facts are undisputed. On or about July 10, 2007, in anticipation of a colonoscopy, Herold ingested a bowel cleansing/purgative product known as OsmoPrep. In November 2007, one of Herold‟s physicians, nephrologist Adarsh Bhat, who had been treating Herold for renal problems since 2006, told Herold that he needed to go on dialysis, that the bowel purgative product should not have been prescribed to him, and that if he had not taken the product he would not need to be on dialysis. Herold began receiving dialysis treatment in January 2008. On November 22, 2010, Herold commenced this action against Salix, the manufacturer of OsmoPrep. As relevant here, Herold asserted causes of action for strict products liability (manufacturing defect and failure to warn), negligence, and negligent

1 Although, as we explain post, the trial court appears to have misstated the test for ascertaining whether the statute of limitations commenced running by omitting the requirement of a suspicion of wrongdoing, we review the result of the trial court‟s decision, not its reasoning. (Florio v. Lau (1998) 68 Cal.App.4th 637, 653.)

2 misrepresentation.2 Herold alleged that the failure of his kidneys was the result of his use of OsmoPrep. He further alleged that the product was defective and that the defect in the product was not revealed to the public until October 2009, when the FDA first required the product to carry a “black box” warning of the risk of acute phosphate nephropathy, and Salix issued a “Dear Healthcare Provider” letter informing prescribing doctors of the new black box warning. In its answer to the complaint, Salix raised 36 affirmative defenses, including the bar of the statute of limitations. In October 2011, Salix moved for summary judgment based on the two-year statute of limitations in Code of Civil Procedure section 335.1.3 Salix argued that, based on the facts we have set forth ante, Herold “knew about the potential for wrongdoing as of November 2007, and he did not file his lawsuit until late November 2010.” According to Salix, based on Herold‟s deposition testimony, Herold “by his own admission, had information in November, 2007 that the bowel-prep product he took prior to his colonoscopy that summer caused him an injury, i.e. caused such kidney failure as to require him to begin dialysis. He therefore had until November 2009 to file the instant lawsuit against the manufacturer of the bowel-prep product.” In opposition to the motion, Herold argued that Salix had not met its initial burden on summary judgment of demonstrating the absence of any triable issue of fact because the evidence on which Salix relied was subject to more than one legitimate inference as to what Herold suspected or should have suspected upon receiving the information from Dr. Bhat in November 2007. Herold also argued that even if Salix had met its burden,

2 Other causes of action included in the complaint were dismissed on Herold‟s request simultaneous with the filing of his opposition to the summary judgment motion. 3 This statute establishes a two-year limitations period for “[a]n action for . . . injury to . . . an individual caused by the wrongful act or neglect of another.” (Code Civ. Proc., § 335.1.)

3 Herold had raised a triable issue of fact by producing evidence that he did not suspect wrongdoing by the manufacturer of OsmoPrep until May 2010 and that in November Dr. Bhat had not “indicate[d] or impl[ied] there was any wrongdoing on the part of [the manufacturer].”4 Herold also asked for leave to amend his complaint if the court found that he had failed to show the existence of a triable issue of fact. The trial court granted Salix‟s motion, concluding that “the statute of limitations began to run in November of 2007” because “[Herold] himself admits to knowledge of his injury and the cause of his injury” as of that date. The court also denied Herold‟s request to amend his complaint, noting that Herold had “presented no possible amendment that would overcome” the bar of the statute of limitations. Herold timely appealed from the resulting judgment.5

4 In opposing Salix‟s motion for summary judgment, Herold failed to comply with the procedural rules. The response to the moving party‟s separate statement must state whether each fact is “disputed” or “undisputed.” (Cal. Rules of Court, rule 3.1350(f); see Code Civ. Proc., § 437c, subd. (b)(3).) Instead, Herold “objected” to certain facts, contending they misstated his deposition. Objections to evidence in papers on a motion for summary judgment must either be made in writing or at the hearing with a court reporter present. (Cal. Rules of Court, rule 3.1352.) The trial court ruled any objection would be overruled and Salix‟s separate statement did not misstate Herold‟s deposition testimony. 5 The document the parties have treated as a judgment in the action is actually entitled “ORDER GRANTING SUMMARY JUDGMENT IN FAVOR OF DEFENDANT SALIX PHARMACEUTICALS, INC.” The body of the document, however, includes the phrase, “Judgment shall hereby be entered in favor of defendant,” and the notice of entry that was served with relation to this document specified that the document constituted both an order granting summary judgment and the judgment itself.

4 DISCUSSION I Standard of Review on Summary Judgment A defendant may move for summary judgment “if it is contended that the action has no merit . . . .” (Code Civ. Proc., § 437c, subd. (a).) “A defendant . . . has met his or her burden of showing that a cause of action has no merit if that party has shown that one or more elements of the cause of action, even if not separately pleaded, cannot be established, or that there is a complete defense to that cause of action. Once the defendant . . . has met that burden, the burden shifts to the plaintiff . . . to show that a triable issue of one or more material facts exists as to that cause of action or a defense thereto.” (Id., subd.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Gutierrez v. Mofid
705 P.2d 886 (California Supreme Court, 1985)
Cobbs v. Grant
502 P.2d 1 (California Supreme Court, 1972)
Jolly v. Eli Lilly & Co.
751 P.2d 923 (California Supreme Court, 1988)
Kilburn v. Pineda
137 Cal. App. 3d 1046 (California Court of Appeal, 1982)
Hills v. Aronsohn
152 Cal. App. 3d 753 (California Court of Appeal, 1984)
Kitzig v. Nordquist
97 Cal. Rptr. 2d 762 (California Court of Appeal, 2000)
Clark v. Baxter Healthcare Corp.
100 Cal. Rptr. 2d 223 (California Court of Appeal, 2000)
Goldrich v. Natural Y Surgical Specialties, Inc.
25 Cal. App. 4th 772 (California Court of Appeal, 1994)
Florio v. Lau
80 Cal. Rptr. 2d 409 (California Court of Appeal, 1998)
Hernandez v. Modesto Portuguese Pentecost Assn.
40 Cal. App. 4th 1274 (California Court of Appeal, 1995)
Tsemetzin v. Coast Federal Savings & Loan Ass'n
57 Cal. App. 4th 1334 (California Court of Appeal, 1997)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
Miller v. Bechtel Corp.
663 P.2d 177 (California Supreme Court, 1983)

Cite This Page — Counsel Stack

Bluebook (online)
Herold v. Salix Pharmaceuticals CA3, Counsel Stack Legal Research, https://law.counselstack.com/opinion/herold-v-salix-pharmaceuticals-ca3-calctapp-2013.